Obsessive–compulsive disorder (OCD) is a chronic mental health condition in which <i>obsessions</i>, which are recurrent and intrusive thoughts, urges or images, and <i>compulsions</i>, which are repetitive behaviours or mental acts performed to reduce the distress they cause, consume substantial time and impair daily functioning. Historically treated as an anxiety disorder, it is now classified in the DSM-5 within a separate chapter on obsessive-compulsive and related disorders. It is one of the more common psychiatric conditions, and it is a significant cause of disability and reduced quality of life, which is why it matters for public health and for health-care systems.
This entry explains how OCD is defined and diagnosed, how common it is and how it typically develops, and how it relates to other conditions such as depression, tic disorders and body-focused repetitive behaviours. It then reviews current explanations of its causes, including genetic, environmental and neurobiological findings centred on cortico-striatal circuits and serotonin signalling, together with cognitive and behavioural models of how obsessions and compulsions are maintained. The article also describes assessment tools, first-line treatments (cognitive behavioural therapy with exposure and response prevention, and serotonin reuptake inhibitor medication), second-line and neuromodulation options for treatment-resistant cases, and the course and outcomes of the disorder. Finally, it addresses the history of the concept, stigma, access to care, and questions that remain unresolved.
Definition and diagnostic criteria
Obsessive–compulsive disorder (OCD) is a mental disorder defined by obsessions, compulsions, or both, together with a threshold of time consumption, distress, or functional impairment. The American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5), published in 2013, sets out four core diagnostic requirements: the characteristic symptoms must be present; they must be time-consuming or clinically significant; they must not result from a substance or another medical condition; and another mental disorder must not better explain them. A text revision, DSM-5-TR, was published in 2022. The definition does not require both obsessions and compulsions to be identified in every case. (psychiatry.org)
Obsessions are recurrent, persistent thoughts, urges, or mental images experienced as intrusive and unwanted, usually producing substantial anxiety or distress. The person attempts to ignore or suppress them, or to neutralise them through another thought or action. Their content can include contamination, responsibility for harm, or unwanted sexual or religious material. For example, an intrusive image of harming someone may be experienced as frightening rather than desired. What identifies an obsession is not its subject matter alone, but its unwanted recurrence, associated distress, and the person’s response to it. Attempts at neutralisation may be visible, such as washing, or entirely mental, such as silently repeating words. (nimh.nih.gov)
Compulsions are repetitive behaviours or mental acts that a person feels compelled to perform in response to an obsession or according to inflexible rules. They aim to reduce distress or prevent a feared outcome, but are either clearly excessive or lack a realistic connection to what they are supposed to prevent. Examples include repeatedly checking locks, washing, arranging objects, counting, praying, and seeking reassurance. A contamination fear may lead to excessive washing; another person may repeat a phrase to avert an unrelated feared event. Compulsions can produce temporary relief without being pleasurable. Consequently, the absence of conspicuous rituals does not establish the absence of compulsions: counting or ritualised prayer may occur silently. (psychiatry.org)
The diagnostic threshold separates OCD from occasional intrusive thoughts, ordinary double-checking, and habitual routines. DSM-5 gives more than one hour per day as an example of time-consuming symptoms, but this is not a mandatory minimum when clinically significant distress or impairment is present. Symptoms occupying less time can therefore meet the threshold if they substantially disrupt work, education, relationships, or other important activities. Conversely, a preference for cleanliness or order is not sufficient by itself: the characteristic symptoms and clinical significance must be established. (ncbi.nlm.nih.gov)
The exclusion requirements concern both cause and explanation. Symptoms attributable to the physiological effects of a drug, medication, or another medical condition do not meet the criteria for primary OCD. Similarly, repetitive thoughts or rituals are insufficient when another disorder better accounts for them—for example, food-related rituals in an eating disorder, appearance preoccupations in body dysmorphic disorder, or repetitive behaviour associated with autism. These exclusions do not prohibit coexisting diagnoses; they require that the symptoms used to diagnose OCD are not better explained by the other condition. (ncbi.nlm.nih.gov)
Reclassification and the DSM-5 framework
DSM-IV, published in 1994, classified OCD among the anxiety disorders. DSM-5, published in 2013, moved it into a separate chapter, “Obsessive-Compulsive and Related Disorders.” The change recognized that persistent preoccupations and repetitive behaviours provide a useful organizing framework beyond anxiety alone. Anxiety remains prominent in many OCD presentations, but the new grouping reflects evidence of relationships among these disorders and distinctions from other anxiety disorders. It was also intended to encourage clinicians to identify related conditions rather than automatically treating all repetitive behaviour as OCD. (psychiatry.org)
The chapter brought together disorders previously distributed across several diagnostic classes. Body dysmorphic disorder, formerly a somatoform disorder, involves preoccupation with perceived appearance defects accompanied by repetitive behaviours or mental acts, such as mirror checking or comparing appearance. Trichotillomania, or hair-pulling disorder, moved from the impulse-control disorders category. Hoarding disorder and excoriation, or skin-picking disorder, became separate diagnoses in DSM-5. These conditions share features with OCD without being interchangeable: hair pulling and skin picking need not be responses to an obsession, and hoarding disorder is not simply an OCD symptom subtype. The chapter also includes substance- or medication-induced presentations and presentations attributable to another medical condition. Classification together does not imply identical mechanisms or identical treatment. (psychiatryonline.org)
DSM-5 expanded the description of insight into three specifiers. “With good or fair insight” means that the person considers the disorder-related beliefs inaccurate, probably inaccurate, or uncertain. “With poor insight” means that those beliefs are considered probably true; “with absent insight/delusional beliefs” means complete conviction that they are true. For example, a person who repeatedly checks a stove may recognize that the checking is unnecessary, believe it probably prevents a fire, or be entirely convinced that a fire will occur without the ritual. The distinction concerns conviction in the belief, not simply the frequency of checking. DSM-5 therefore does not require recognition of the irrationality of symptoms as a prerequisite for an OCD diagnosis. Disorder-specific beliefs of delusional intensity can be classified within OCD rather than automatically establishing a separate psychotic disorder. (ncbi.nlm.nih.gov)
The tic-related specifier applies when there is a current or past history of a tic disorder; active tics at the assessment are not required. It records a clinically relevant developmental history rather than creating a separate diagnostic category. Both tic history and insight enter treatment assessment: limited insight may complicate engagement, while tic-related presentations can differ in their clinical course and treatment response. These specifiers do not themselves prescribe a medication or psychological intervention. The framework separates such modifiers from the core diagnosis, allowing clinicians to document meaningful differences among people who meet the same OCD criteria. (ncbi.nlm.nih.gov)
“Other specified obsessive-compulsive and related disorder” and “unspecified obsessive-compulsive and related disorder” are residual categories for clinically significant presentations that do not meet the full criteria for a named disorder in the chapter. With “other specified,” the clinician records the particular reason or presentation—for example, impairing body-focused repetitive behaviour involving recurrent lip biting, or a body-dysmorphic-like presentation without repetitive behaviours. “Unspecified” is used when the reason is not stated or information is insufficient for a more specific diagnosis, as may occur during an emergency assessment. Both categories retain a requirement for significant distress or functional impairment: they are not labels for ordinary habits, preferences, or occasional intrusive thoughts. Their distinction communicates the specificity of the assessment, not a fixed difference in severity. (w1.med.cmu.ac.th)
Symptom dimensions and presentation
OCD symptoms cluster into overlapping dimensions, rather than mutually exclusive clinical subtypes. Common groupings include contamination and cleaning, harm and checking, symmetry and ordering, and unwanted sexual, religious or aggressive thoughts. A person may experience several dimensions simultaneously, and the content of obsessions or the associated rituals may change over time. These familiar groupings do not capture every presentation: a study by Matti Cervin and colleagues, first published online in 2021, analysed 87 symptoms in 1,366 individuals and identified 13 narrower dimensions that could be grouped into eight broader dimensions, including disturbing thoughts, incompleteness, contamination and hoarding. The findings illustrate both the recurring structure and the heterogeneity of symptoms. (infocenter.nimh.nih.gov)
Contamination symptoms involve fears of germs, illness or spreading contamination, commonly accompanied by repeated washing or cleaning. Cleaning may be driven by disgust as well as by fear of disease; these motivations need not coincide. Harm-and-checking symptoms include persistent doubts about whether a door has been locked or an appliance switched off, with repeated inspection intended to prevent a feared consequence. Symmetry and “just right” symptoms involve arranging, counting or repeating actions until they feel sufficiently exact or complete. Unlike rituals directed towards a specific catastrophe, these actions may respond primarily to an uncomfortable sense of incompleteness or a perceptual feeling that something is wrong. Cervin and colleagues distinguished accuracy, perceptual phenomena and “not just right” behaviours within the broader incompleteness dimension. (infocenter.nimh.nih.gov)
Taboo obsessions take the form of unwanted intrusive thoughts, images or urges concerning sex, violence, blasphemy or moral wrongdoing. Their content is not, by itself, evidence of a wish or intention to act: NICE guidance notes that sexual, aggressive and death-related intrusions are common in OCD and are often misinterpreted as indicating risk. Religious or moral presentations are sometimes called scrupulosity; the relevant distinction is between distressing obsessive demands and the person’s ordinary religious or cultural practices. Shame and fear of judgment may inhibit disclosure. Hoarding symptoms also appear in historical and research descriptions of OCD, but hoarding disorder is a separate diagnosis and should not be treated as synonymous with an OCD symptom dimension. (nice.org.uk)
Compulsions can be overt, such as washing, checking and arranging, or covert, such as silently counting, repeating words or praying. Mental rituals are identified by their repetitive, driven function rather than by their visibility: praying, for example, can function as a compulsion when repeatedly performed to neutralise an obsession. Reassurance-seeking can likewise become ritualised, with repeated requests for confirmation that an event is safe or that no harm has occurred. Avoidance is another important part of presentation, although it is not identical to a ritual: people may stay away from situations that trigger obsessions, thereby making the extent of their symptoms less apparent. NICE guidance explicitly addresses both mental neutralising strategies and relatives’ participation in reassurance-seeking or avoidance. (infocenter.nimh.nih.gov)
Insight concerns how accurately a person recognises the unreasonable or excessive nature of OCD-related beliefs. It ranges from recognising that feared consequences are probably untrue to being convinced that they are true. Recognition does not necessarily remove the urge to ritualise: an individual may regard repeated checking as excessive yet remain unable to tolerate stopping. Conversely, when rituals seem necessary protection rather than symptoms, recognition of a need for care and engagement with treatment may be more difficult. In a study of treatment nonadherence, poorer insight was associated with poorer adherence to medication; this association does not establish that poor insight caused nonadherence. (psychiatry.org)
Insight itself is not necessarily fixed. A 2023 report from the Netherlands Obsessive Compulsive Disorder Association study followed 253 patients over four years and examined changes in insight alongside symptom severity and quality of life. Improvement in insight was associated with improvement in OCD severity. Such longitudinal findings support distinguishing the person’s current conviction about an obsession from an assumed permanent characteristic of their presentation. (pmc.ncbi.nlm.nih.gov)
Epidemiology and developmental course
Lifetime prevalence estimates for obsessive–compulsive disorder (OCD) commonly fall around 1–3%, although this is not a universal range. In the United States, A. M. Ruscio and colleagues’ National Comorbidity Survey Replication analysis, published in 2010, assessed 2,073 adults and estimated lifetime prevalence at 2.3% and 12-month prevalence at 1.2%. More than one quarter reported having experienced obsessions or compulsions, demonstrating how much more common isolated symptoms are than the full disorder. Differences in interview instruments, diagnostic thresholds and the handling of subthreshold symptoms therefore substantially affect estimates. (pubmed.ncbi.nlm.nih.gov) A 2025 World Mental Health survey analysis of 26,136 adults across ten countries found higher combined estimates: 4.1% lifetime and 3.0% 12-month prevalence. Its inclusion of predominantly mild community cases, together with differences in samples and ascertainment, limits direct comparison with older surveys; the combined figure is not an estimate for the entire world population. (bmcmedicine.biomedcentral.com)
Onset is concentrated in childhood, adolescence and early adulthood, but the distribution differs between populations and between definitions of first symptoms and first diagnosable disorder. A frequently described bimodal pattern comprises an early peak in childhood or early adolescence and a later peak in late adolescence or young adulthood. In a large clinical sample reported in 2014, G. E. Anholt and colleagues identified two onset distributions, with age 20 providing the best-fitting boundary between early- and late-onset groups. This statistical division is not a diagnostic cutoff. (pubmed.ncbi.nlm.nih.gov) Mean onset is commonly placed around ages 19–20; males are disproportionately represented among childhood-onset cases, whereas adult OCD is slightly more common among females. Approximate peaks around ages 11 and 23 are useful descriptions rather than fixed developmental milestones. (msdmanuals.com)
The developmental course often involves gradual emergence followed by persistent symptoms whose severity waxes and wanes. A chronic course does not imply continuously severe illness: periods of reduced interference may alternate with exacerbations, and residual symptoms can remain below the diagnostic threshold. Episodic courses with symptom-free intervals also occur. (pmc.ncbi.nlm.nih.gov) In the 2025 World Mental Health analysis, 74.1% of respondents with lifetime OCD also met criteria during the preceding year, supporting substantial persistence at population level. This cross-sectional measure cannot establish uninterrupted illness or distinguish persistent symptoms from recurrence after remission. (bmcmedicine.biomedcentral.com)
Recognition and treatment commonly lag behind onset by several years. A 2025 meta-analysis of 31 studies estimated the mean age at help-seeking at 28.66 years and the mean interval between disorder onset and help-seeking at 6.97 years. The pooled duration of untreated illness—defined as the interval before adequate treatment—was 80.23 months, approximately 6.7 years. These measures should not be equated with delay to formal diagnosis, because initial consultation, diagnostic recognition and adequate treatment can occur at different times. (sciencedirect.com) Gradual onset, concealment of symptoms, expectations that symptoms will disappear spontaneously, and limited availability of appropriate mental health services contribute to these delays. (pmc.ncbi.nlm.nih.gov)
Cross-cultural research identifies OCD in diverse settings while also showing variation in measured frequency and symptom content. A 1994 comparison using similar DSM-III methods across seven countries or territories found annual prevalence between 1.1% and 1.8%, except in Taiwan, where it was 0.4%; onset patterns were broadly comparable. (pubmed.ncbi.nlm.nih.gov) Cultural and religious practices can supply the content around which symptoms develop without themselves constituting pathology. For example, O. M. Mahgoub and H. B. Abdel-Hafeiz’s 1991 study of 32 Muslim Saudi patients found religious themes predominating in both obsessions and compulsions. (pubmed.ncbi.nlm.nih.gov) A 2011 qualitative study of young Muslim women in Saudi Arabia documented symptoms involving prayer and rigid religious observance. Such clinical findings describe particular samples, not the prevalence of OCD among adherents of a religion, and do not establish religious practice as a cause of the disorder. (tandfonline.com)
Comorbidity and differential diagnosis
Co-occurring psychiatric disorders are common, but lifetime comorbidity does not necessarily mean that both disorders are active simultaneously. In the United States National Comorbidity Survey Replication, conducted in 2001–2003, A. M. Ruscio and colleagues found that 90% of respondents with lifetime DSM-IV OCD also met criteria for another lifetime disorder: 75.8% had an anxiety disorder, 63.3% a mood disorder, and 38.6% a substance use disorder. Major depressive disorder accounted for 40.7%; bipolar disorders were also associated with OCD. These estimates came from structured household interviews rather than a specialist clinical sample and should not be treated as universal rates. (cpb-us-w2.wpmucdn.com) Eating disorders and tic disorders are additional recognized co-occurring conditions. (psychiatry.org)
Differential diagnosis depends on the content and function of symptoms, not simply their repetitiveness. In generalized anxiety disorder, worry chiefly concerns everyday events; OCD involves intrusive, unwanted thoughts, urges, or images. Poor or absent insight alone does not establish schizophrenia: hallucinations, disorganized thought, and the wider clinical presentation help distinguish psychotic disorders. Eating-disorder rituals principally concern food, weight, or shape; an additional OCD diagnosis requires symptoms not better explained by that disorder. Both diagnoses can coexist when their respective requirements are met. (drugsandalcohol.ie)
Body-focused repetitive behaviours, particularly hair pulling and skin picking, can resemble compulsions but are not automatically manifestations of OCD. Pulling or picking may occur automatically or in response to an urge, tension, or a perceived irregularity in hair or skin, rather than to neutralize an obsession. (psychiatry.org) Tic disorders, including Tourette syndrome, present another overlap. A 2001 comparative study found that repetitive behaviours in OCD were associated with more anxiety and goal-directedness than those in Tourette syndrome; participants with both OCD and tics occupied an intermediate position. Thus, touching or repeating a movement cannot be classified solely from its outward appearance. (pubmed.ncbi.nlm.nih.gov)
Repetitive behaviours in autism spectrum disorder likewise require examination of their developmental context and purpose. A 1995 study by Christopher McDougle and colleagues compared 50 autistic adults with 50 age- and sex-matched adults with OCD without tics. The autistic group showed more repetitive ordering, touching, tapping, or rubbing, but fewer contamination, aggressive, sexual, and religious thoughts and less cleaning, checking, and counting. These group differences do not classify every individual behaviour; assessment also considers social-communication development and whether a distinct obsession–compulsion pattern is present. (pubmed.ncbi.nlm.nih.gov)
Medication exposure can complicate the distinction between comorbid OCD and secondary obsessive-compulsive symptoms. Clozapine-associated onset or worsening has been reported, but observational findings do not establish that every symptom emerging during treatment was caused by the drug. A study of changes during the year before and after clozapine initiation illustrates the importance of documenting the preceding symptom history, rather than inferring causation from medication use alone. (pmc.ncbi.nlm.nih.gov)
Substance-induced symptoms and symptoms secondary to medical conditions are classified separately from primary OCD. ICD-11 identifies amphetamine intoxication as a possible cause of obsessions or compulsions. Establishing a secondary syndrome requires an explanatory exposure or illness and a temporal relationship to symptom onset. Sudden or late onset, cognitive impairment, or focal neurological signs can support investigation of a medical cause. Examples include stroke, brain injury, epilepsy, and Huntington disease; merely having one of these conditions does not establish that it caused the obsessive-compulsive symptoms. (drugsandalcohol.ie)
Causes and risk factors
Family and twin studies support a substantial contribution from genetic variation. In a 2013 Swedish register study, David Mataix-Cols and colleagues identified 24,768 people diagnosed with OCD and found that relatives’ risk increased with their degree of genetic relatedness. Separate analyses of 16,383 twins estimated heritability at 47% (95% confidence interval, 42–52%), without a statistically significant contribution from shared household environment. Estimates for obsessive–compulsive symptoms in childhood commonly range from 45% to 65%. Heritability describes variation within a population under particular environmental conditions; it does not mean that this percentage of an individual’s disorder is genetically caused or that symptoms are inevitable. A small estimated shared-environment component also does not exclude effects of experiences that differ between siblings. (pubmed.ncbi.nlm.nih.gov)
Molecular studies indicate a polygenic architecture rather than a single major “OCD gene.” A 2025 genome-wide association study meta-analysis combined 53,660 cases and 2,044,417 controls from 28 cohorts and identified 30 independently associated genomic regions. These associations locate statistical signals, not necessarily the causal genes or biological mechanisms within those regions. Important limitations include the restriction to European-ancestry samples and differences in case ascertainment: 20,427 cases had clinician-assessed or health-record diagnoses, whereas 32,233 were based on self-reported diagnoses. Such findings establish population-level genetic associations but do not provide a definitive individual diagnostic test or a simple explanation for why a particular person develops symptoms. (pmc.ncbi.nlm.nih.gov)
Early adversity and stressful life events are associated with symptoms, although association does not by itself establish causation. A 2015 study of 22,084 Swedish twins found that an “abuse and family disruption” factor remained associated with symptom severity when identical twins were compared, controlling for their shared genetic background. The association was modest, explaining approximately 3% of symptom variation, and exposure was retrospectively reported. Stronger temporal evidence came from Georgina Krebs, Laurie Hannigan and colleagues’ 2019 longitudinal study, which assessed 2,616 twins and siblings at a mean age of 15 and reassessed 1,579 at approximately 17. Stressful events predicted subsequent increases in symptoms after adjustment for earlier symptoms; punitive parenting did not independently predict that change. These results do not support treating a particular parenting style as an established cause of OCD. (sciencedirect.com)
Temperament may mark developmental vulnerability, but the evidence is not specific to a single personality profile. A 2011 analysis of the Dunedin birth cohort assessed OCD at ages 26 and 32, identifying 36 affected participants. Negative emotionality measured at age 18 and childhood social isolation predicted adult OCD relative to both healthy and other anxious comparison groups. Difficult early-childhood temperament was associated particularly with the later harm/checking symptom dimension. The small number of OCD cases and differences between symptom dimensions limit generalisation. These prospective associations distinguish possible antecedents from personality characteristics measured during an active episode, when symptoms themselves may affect reported temperament. (pubmed.ncbi.nlm.nih.gov)
Infection-triggered childhood presentations remain an area of uncertainty. Pediatric acute-onset neuropsychiatric syndrome (PANS) describes abrupt onset of OCD or severely restricted eating alongside other acute neuropsychiatric symptoms. Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) proposes a narrower presentation temporally associated with group A streptococcal infection, with OCD and/or tics. The hypothesised mechanism is a postinfectious immune response affecting neural function. The American Academy of Pediatrics’ 2025 clinical report states that PANS lacks disease-specific biomarkers and strong evidence establishing its pathogenic causes. A 2024 Swedish population study likewise found that the association between severe childhood infections and later OCD was largely explained by shared familial factors. Infection preceding symptoms therefore does not, by itself, establish an autoimmune cause. (publications.aap.org)
Interaction models distinguish inherited susceptibility, exposure to stress and the learning processes that sustain rituals. One proposed pathway is that stress increases threat sensitivity and distress, while rituals acquire value because they temporarily reduce arousal. This is a model of symptom development and maintenance rather than proof of a particular genetic–environmental interaction. Genetic influences can also affect exposure to stressful circumstances: the 2019 adolescent twin study attributed the association between life events and symptom change to both genetic and non-shared environmental influences, in approximately equal proportions. Consequently, an apparently environmental risk association may include genetic confounding as well as a genuinely environmental component. (pmc.ncbi.nlm.nih.gov)
Neurobiology and brain circuits
Cortico-striato-thalamo-cortical (CSTC) circuit models locate OCD-related dysfunction in interconnected loops rather than a single brain region. These loops link the orbitofrontal and anterior cingulate regions of the cerebral cortex with the striatum, pallidum and thalamus, which returns signals to the cortex. Within basal-ganglia circuitry, the direct pathway facilitates thalamocortical activity through disinhibition, whereas the indirect pathway increases inhibition of thalamic output. A classical hypothesis proposes that excessive direct-pathway activity relative to indirect-pathway activity sustains recurrent thoughts and actions. This is a proposed mechanism, not an established abnormality shared by all patients. Parallel circuits supporting valuation, cognitive control and sensorimotor behaviour also make the model more complex than a uniformly “overactive loop”. (nature.com)
Functional imaging provides evidence for altered activity in these systems, particularly when symptoms are experimentally provoked. A quantitative analysis of eight symptom-provocation studies identified convergent activation in the bilateral orbitofrontal and anterior cingulate cortices, alongside pallidal and other regions. A subsequent meta-analysis of 25 emotional-processing studies found abnormalities extending into the amygdala and temporal cortex; medication status and co-occurring mood or anxiety disorders influenced the results. Consequently, imaging findings depend partly on whether participants are resting, viewing symptom-related material or performing a cognitive task. Small samples, different symptom profiles, medication exposure and differences in imaging analysis further limit agreement between studies. (pmc.ncbi.nlm.nih.gov)
Structural magnetic resonance imaging likewise shows subtle, developmentally variable group differences. In the ENIGMA-OCD study published in the January 2017 issue of the American Journal of Psychiatry, Premika Boedhoe and colleagues found smaller hippocampal volumes and larger pallidal volumes in adults with OCD, with small standardized effects: Cohen’s and , respectively. Both differences were greater in medicated groups, although this association does not establish that medication caused them. Unmedicated children and adolescents had larger thalamic volumes than controls, with . These contrasting patterns caution against treating adult and paediatric OCD as neuroanatomically identical, or interpreting a group-average finding as an individual diagnostic marker. (psychiatryonline.org)
The serotonergic hypothesis derives partly from the clinical effects of serotonin-reuptake inhibitors, but treatment response does not establish a simple serotonin deficiency. Direct molecular-imaging results differ: a 2003 positron emission tomography study of 11 medication-free patients and 11 controls found no significant serotonin-transporter differences, whereas a 2007 study using a different tracer found reduced transporter availability in the thalamus and midbrain of nine patients compared with 19 controls. Glutamate hypotheses concern excitatory signalling within cortical–striatal networks. In 2023, Marjan Biria and colleagues used 7-tesla proton magnetic resonance spectroscopy and found higher glutamate and lower GABA concentrations in the anterior cingulate cortex of participants with OCD. These regional metabolite measurements support investigation of excitation–inhibition balance, but do not directly measure neurotransmitter release at individual synapses. (pubmed.ncbi.nlm.nih.gov)
Neuropsychological experiments connect circuit models to error detection, response inhibition and action control. A 2019 imaging meta-analysis found increased dorsal anterior cingulate and supplementary motor-region activation during error processing, but reduced recruitment of several control-related regions during inhibition; behavioural differences were modest, with standardized effects of approximately 0.20–0.22 for inhibitory reaction time and errors. Habit-based accounts address a different problem: actions continuing despite changes in their consequences. In Claire Gillan and colleagues’ 2011 experiment, 21 patients and 30 controls learned responses that earned pictured rewards. Patients learned successfully from feedback but subsequently made more “slips of action” toward outcomes that no longer earned rewards. This finding supports an imbalance between goal-directed and habitual control; it does not by itself distinguish stronger habits from weaker knowledge or use of action–outcome relationships. (pmc.ncbi.nlm.nih.gov)
Cognitive and behavioural models
Cognitive appraisal models locate the transition from an intrusive thought to an obsession in the meaning assigned to the intrusion, rather than in its content alone. Paul Salkovskis’s 1985 formulation emphasised inflated responsibility: the belief that a person has a special obligation to prevent harm and may be blameworthy for failing to do so. Stanley Rachman’s 1997 theory emphasised catastrophic interpretations of thoughts, images and impulses as revealing something important about personal character or danger. In these accounts, an unwanted image of harming someone becomes distressing when interpreted as evidence of dangerousness or as a warning requiring preventive action. Neutralising the thought then becomes an apparent moral or practical necessity. (sciencedirect.com)
The overimportance of thoughts includes treating an intrusion as significant simply because it occurred, while the perceived need to control thoughts makes their recurrence appear to represent failure. A related construct, thought–action fusion, was investigated by Roz Shafran, Dana Thordarson and Rachman in 1996. Its moral form equates thinking about an unacceptable act with committing it; its likelihood form treats the thought as increasing the probability of an adverse event. These are interpretations of thoughts, not evidence of intent or causal influence. Intolerance of uncertainty and perfectionism provide another route to rituals: unresolved doubt or the possibility of an error becomes unacceptable, encouraging further checking even when ordinary evidence is sufficient. A 2005 study by the Obsessive Compulsive Cognitions Working Group, including 410 OCD outpatients, identified three broad belief clusters: responsibility/threat estimation, perfectionism/uncertainty, and importance/control of thoughts. These overlapping domains are research constructs, not separate diagnostic subtypes. (sciencedirect.com)
Behavioural learning accounts explain persistence through negative reinforcement. A trigger evokes distress; washing, checking or mental neutralisation reduces that distress temporarily; the reduction makes the response more likely when the trigger returns. “Negative” refers to removing an aversive state, not to punishment. For example, relief after checking a locked door can strengthen checking without establishing that repeated checks prevented a burglary. The immediate benefit competes with the longer-term opportunity to discover that uncertainty and distress can be experienced without a ritual. Cognitive and behavioural accounts therefore describe complementary parts of a cycle: threatening interpretations motivate compulsions, while the consequences of compulsions help preserve those interpretations. (pmc.ncbi.nlm.nih.gov)
Avoidance and safety-seeking behaviours can maintain the same cycle without a conspicuous ritual. Avoiding a supposedly contaminated object prevents direct testing of the feared prediction; seeking reassurance or silently cancelling a thought can allow a safe outcome to be attributed to the protective response. Their maintaining role is a model prediction rather than an inevitable consequence of every precaution. Rituals may also worsen the problem they seek to solve. In 2003, Marcel van den Hout and Merel Kindt conducted two experiments with 39 and 40 healthy participants using a virtual gas stove. Repeated relevant checking reduced memory confidence, vividness and detail without reducing memory accuracy, providing an experimental example of how checking can generate further doubt. The non-clinical samples limit direct generalisation to patients. (sciencedirect.com)
These models supplied rationales for targeted cognitive behavioural therapy. Cognitive interventions examine interpretations of responsibility, danger and thought significance; behavioural experiments test predictions rather than provide repeated reassurance. Exposure and response prevention interrupts avoidance and ritualised relief, creating opportunities for corrective learning. Treatment success, however, does not by itself establish which proposed mechanism produced improvement. A 2016 study of 70 patients receiving exposure and response prevention found that changes in the three measured obsessive-belief domains did not mediate subsequent symptom reduction. Thus, belief change is a plausible therapeutic target, but is not established as the necessary pathway through which exposure-based treatment works. (researchgate.net)
Assessment and measurement
Clinical diagnosis is distinguished from screening and severity measurement. Semi-structured interviews, including the Structured Clinical Interview for DSM-5 Disorders (SCID-5) and the Anxiety and Related Disorders Interview Schedule for DSM-5 (ADIS-5), organise questioning around diagnostic criteria while permitting clarification of individual experiences. Assessment establishes the presence of obsessions, compulsions, or both; their duration, distress and interference; and whether another disorder, substance or medical condition better explains them. The DSM-5 threshold includes symptoms occupying more than one hour daily or producing clinically significant distress or impairment, so time alone is insufficient. Interviews also examine covert rituals, avoidance, insight and co-occurring conditions. A positive questionnaire screen does not independently establish OCD. (pmc.ncbi.nlm.nih.gov)
The Yale–Brown Obsessive Compulsive Scale (Y-BOCS), introduced by Wayne K. Goodman and colleagues in 1989, separates symptom identification from severity rating. Its core clinician-rated scale contains ten items: five for obsessions and five for compulsions, addressing time occupied, interference, distress, resistance and control. Each item is scored from 0 to 4, producing obsession and compulsion subscores of 0–20 and a total of 0–40. Ratings concern the preceding week rather than the patient’s worst lifetime episode. Because severity is rated independently of particular symptom themes, repeated administrations can quantify change even when the content of obsessions changes. The original validation studies demonstrated reliability, validity and sensitivity to treatment-related improvement. (brainphysics.com)
Self-report instruments provide complementary, less resource-intensive measurements. Edna B. Foa and colleagues’ 2002 Obsessive–Compulsive Inventory–Revised (OCI-R) contains 18 items and six subscales. Its initial validation included 215 patients with OCD, 243 with other anxiety disorders and 677 nonanxious participants, allowing assessment of discrimination as well as reliability. Jonathan S. Abramowitz and colleagues developed the 20-item Dimensional Obsessive–Compulsive Scale (DOCS) in 2010. It measures contamination, responsibility for harm or mistakes, unacceptable thoughts, and symmetry or incompleteness. Within each dimension, questions assess time, avoidance, distress, interference and difficulty disengaging from symptoms. Such measures describe symptom profiles and can track change, but their scores are not interchangeable with clinician-rated Y-BOCS totals. (pubmed.ncbi.nlm.nih.gov)
Symptom checklists help elicit experiences that broad questions may miss, including mental reviewing, silent counting and unwanted sexual or religious thoughts. They identify treatment targets rather than merely counting how many symptoms are present. Insight and family accommodation require additional assessment. The Brown Assessment of Beliefs Scale, developed by Jane L. Eisen and colleagues in 1998, measures conviction and insight; its validation showed that these were distinguishable from overall symptom severity. The Family Accommodation Scale examines relatives’ participation in rituals and modifications of daily routines, such as providing repeated reassurance or facilitating avoidance. Its 1999 development study assessed 36 adult patients and their primary caregivers. These measurements capture clinically important features not adequately represented by a single symptom total. (pmc.ncbi.nlm.nih.gov)
In randomized controlled trials, response denotes improvement from baseline, whereas remission denotes a low residual symptom level. A 2016 international expert consensus led by David Mataix-Cols operationalised response as a reduction of at least 35% on the Y-BOCS or its children’s version, together with a Clinical Global Impression–Improvement rating of 1 or 2, sustained for at least one week. Remission was defined as no longer meeting diagnostic criteria; where a diagnostic interview was unavailable, the operational alternative was a score of 12 or below plus a Clinical Global Impression–Severity rating of 1 or 2 for at least one week. Thus, response does not necessarily imply remission: a decline from 32 to 20 exceeds the percentage threshold but leaves substantial symptoms. (onlinelibrary.wiley.com)
Outcome estimates depend on the definitions selected. An analysis by Samantha G. Farris and colleagues, published in 2013 and pooling 288 participants from four treatment trials, identified a 35% Y-BOCS reduction as the best predictor of global improvement, but a post-treatment score of 14 or below as the best predictor of symptom remission. A threshold of 12 or below best predicted a broader “wellness” outcome incorporating quality of life and adaptive functioning. Reports therefore need to distinguish continuous score change, categorical response, remission and functional outcomes, and specify assessment timing rather than treating a single endpoint score as evidence of sustained recovery. (pubmed.ncbi.nlm.nih.gov)
Cognitive behavioural therapy and exposure and response prevention
Exposure and response prevention (ERP), usually delivered within cognitive behavioural therapy (CBT), is the most established psychological treatment for OCD. Exposure involves deliberately encountering situations, objects, thoughts or images that provoke obsessions; response prevention involves refraining from the overt or mental rituals used to neutralise distress. Traditional explanations emphasise habituation—the reduction of anxiety during repeated encounters—and extinction of learned fear responses. An inhibitory-learning account instead proposes that exposure establishes new learning that competes with, rather than erases, existing threat associations. Treatment therefore includes learning that uncertainty and distress can be tolerated without compulsions; an immediate decline in anxiety is not necessary for an exposure to be useful. (iocdf.org)
Treatment begins with assessment of triggers, feared consequences, rituals and avoidance, followed by a shared explanation of the treatment rationale and discussion of willingness to undertake challenging tasks. Therapist and patient construct a hierarchy of situations ranked by anticipated difficulty. Exposures generally progress from manageable tasks to more demanding ones, with repeated practice between appointments. Situational exposure confronts actual triggers; imaginal exposure uses feared thoughts or scenarios that cannot appropriately be reproduced in reality. In contamination-focused treatment, for example, exposure may involve contact with an ordinarily safe object while refraining from ritualised washing. Response prevention also targets covert neutralisation, such as mentally reviewing events or repeating reassuring phrases, rather than merely suppressing visible behaviour. Exposures are collaboratively agreed, not imposed through coercion or deception. (iocdf.org)
Engagement with between-session practice is an important correlate of outcome. A 2020 study of 50 adults receiving twice-weekly ERP found that greater homework adherence predicted post-treatment improvement in harm-responsibility, unacceptable-thought and symmetry symptoms, although the association was not found for contamination symptoms or maintained at follow-up. Michael Wheaton and colleagues’ 2018 analysis found that greater pretreatment avoidance predicted poorer outcomes among 40 adults receiving ERP, even after accounting for initial symptom severity; homework adherence statistically mediated this association. Insight is a less consistent predictor. A secondary analysis involving 163 adults with treatment-resistant OCD found that baseline insight did not predict severity immediately after concentrated exposure treatment or at three months, but poorer insight was associated with greater severity at 12 months. These findings describe associations, not fixed determinants of an individual’s response. (sciencedirect.com)
Individual and group formats both have controlled-trial support. A randomised comparison published online in 2010 assigned 110 outpatients to 15 sessions of group or individual CBT. Both formats produced large improvements on the Yale–Brown Obsessive Compulsive Scale (Y-BOCS), with no significant between-group differences through 12-month follow-up. Intensive delivery compresses therapist-supported exposure into a shorter period. In a 2019 randomised controlled trial of the Bergen four-day treatment, 48 participants were allocated equally to concentrated ERP, self-help or waiting-list conditions. Immediately after treatment, 93.8% of the concentrated-treatment group met the study’s response criterion and 62.5% met its remission criterion, compared with 12.5% and 6.3%, respectively, in self-help. The small sample and absence of a standard weekly-ERP comparison limit conclusions about superiority over conventional treatment schedules. (pubmed.ncbi.nlm.nih.gov)
Internet-based programmes differ from live video treatment: the former commonly organise therapy around written modules and assignments, whereas video sessions permit synchronous therapist coaching. Lina Lundström and colleagues’ 2022 trial allocated 120 adults to 14 weeks of therapist-guided internet CBT, unguided internet CBT or individual face-to-face CBT. At three-month follow-up, guided internet treatment was 2.10 Y-BOCS points worse than face-to-face treatment, but its confidence interval crossed the prespecified three-point noninferiority boundary, leaving noninferiority unproven. Unguided treatment was 5.35 points worse. A smaller 2014 trial by Patrick Vogel and colleagues randomised 30 adults to videoconference-assisted ERP, self-help or waiting list; video treatment produced significantly greater symptom reductions than either control. That pilot supports feasibility and efficacy, but does not establish equivalence to in-person ERP. (pubmed.ncbi.nlm.nih.gov)
Pharmacological treatment
Selective serotonin reuptake inhibitors (SSRIs) are first-line medications for OCD; established options include fluoxetine, fluvoxamine, paroxetine and sertraline. They inhibit the transporter responsible for neuronal reuptake of serotonin, increasing its availability outside neurons. This pharmacological action does not establish that OCD results from a simple serotonin deficiency. Treatment trials generally allow approximately 12 weeks before judging an adequate course unsuccessful, because improvement can develop gradually. Initial anxiety, agitation and restlessness require monitoring, particularly after treatment begins or doses change; gastrointestinal symptoms and sexual dysfunction are additional important adverse effects. (nice.org.uk)
Dose optimization is particularly important in OCD, where higher doses within the therapeutic range may provide additional benefit. In two 13-week fluoxetine trials published in 1994, involving 355 participants, doses of 20, 40 and 60 mg/day were compared with placebo; improvement tended to be greater at 60 mg/day. Doses above licensed limits have also been investigated, but constitute off-label treatment rather than routine prescribing. Philip Ninan and colleagues’ 2006 randomized controlled trial assigned 66 nonresponders after 16 weeks of sertraline to either continued treatment at 200 mg/day or 250–400 mg/day for another 12 weeks. Higher dosing produced greater average symptom reduction, but endpoint response rates—40% versus 33%—were not significantly different. Thus, improvement in mean severity scores does not necessarily imply a demonstrably larger proportion of responders. (pubmed.ncbi.nlm.nih.gov)
Clomipramine, a tricyclic antidepressant with strong serotonin-reuptake inhibition, is effective but commonly used after an SSRI has proved ineffective or poorly tolerated. Other tricyclic antidepressants are not interchangeable substitutes: NICE guidance does not recommend their routine use for OCD without another indication. Clomipramine’s adverse-effect profile includes dry mouth, constipation, sedation, sexual dysfunction and orthostatic hypotension; cardiac conduction abnormalities, seizures and toxicity in overdose are significant safety concerns. Its prescribing information sets an adult maximum of 250 mg/day. NICE specifies cardiovascular assessment, including an electrocardiogram, before treatment in adults at significant cardiovascular risk. These tolerability and safety considerations distinguish it from first-line SSRIs despite its established efficacy. (nice.org.uk)
For persistent symptoms despite an adequate serotonin-reuptake inhibitor trial, augmentation adds a second treatment while retaining the original medication. Low-dose risperidone and aripiprazole have supporting evidence, although benefit is not uniform across antipsychotics or patients. Markus Dold and colleagues’ 2015 meta-analysis included 14 placebo-controlled trials and 491 participants: antipsychotic augmentation reduced symptom severity more than placebo, with a standardized effect size of approximately 0.64. Risperidone, aripiprazole and haloperidol individually showed significant benefits; quetiapine, olanzapine and paliperidone did not. Short trials leave uncertainty about long-term benefit and tolerability. Other augmentation approaches have yielded conflicting findings: an early placebo-controlled memantine study reported benefit, whereas a 2022 trial involving 70 participants found no additional reduction in OCD symptoms when memantine was added to sertraline. (pubmed.ncbi.nlm.nih.gov)
Combining medication with exposure and response prevention (ERP), a form of cognitive behavioural therapy, can improve outcomes over medication alone, but medication does not consistently improve outcomes over well-delivered ERP alone. In Edna Foa and colleagues’ 2005 trial of 122 adult outpatients, response rates among treated participants were 62% with intensive ERP, 42% with clomipramine, 70% with their combination and 8% with placebo; ERP and combined treatment did not differ significantly. Conversely, Helen Blair Simpson and colleagues’ 2013 trial studied 100 adults with significant residual symptoms despite serotonin-reuptake inhibitor treatment. After eight weeks, response, defined as at least a 25% reduction in severity, occurred in 80% receiving added ERP, 23% receiving risperidone and 15% receiving placebo. These trials distinguish the demonstrated benefit of adding ERP to medication from the less consistent incremental benefit of adding medication to ERP. (pubmed.ncbi.nlm.nih.gov)
Neuromodulation and surgical options
Repetitive transcranial magnetic stimulation (rTMS) uses an external coil to generate magnetic pulses that induce electrical currents in brain tissue without implantation or tissue destruction. OCD protocols differ in their cortical targets, stimulation frequency and coil geometry. A pivotal randomized controlled trial led by Lior Carmi, published in 2019, allocated 99 patients to active or sham deep TMS targeting the medial prefrontal and anterior cingulate cortices. Treatment consisted of daily 20-Hz sessions for six weeks, preceded by individualized symptom provocation intended to activate relevant circuits. Response, defined as at least a 30% reduction on the Yale–Brown Obsessive Compulsive Scale (Y-BOCS), occurred in 38.1% of the active group and 11.1% of the sham group after treatment. The US Food and Drug Administration (FDA) authorized marketing of the BrainsWay system for OCD on August 17, 2018. Headache and transient local discomfort were common; no serious device-related adverse reactions were reported in the pivotal study. These results establish efficacy for a particular protocol rather than for all forms of TMS. (psychiatryonline.org)
Other non-invasive approaches remain less established. Transcranial direct current stimulation (tDCS) delivers weak electrical current through scalp electrodes to alter cortical excitability. In a 2024 French multicentre trial led by Ghina Harika-Germaneau, 80 treatment-resistant patients received ten active or sham sessions, with the cathode over the supplementary motor area. The primary endpoint—Y-BOCS change after two weeks—was not met. Although a secondary symptom-score endpoint favoured active stimulation at three months, responder and remission proportions did not differ significantly. This distinction between statistical symptom change and clinically meaningful response limits conclusions about efficacy. (pubmed.ncbi.nlm.nih.gov)
Deep brain stimulation (DBS) involves surgically implanted electrodes connected to a programmable pulse generator. Investigated targets include the ventral capsule/ventral striatum, nucleus accumbens and subthalamic nucleus; stimulation seeks to modulate distributed circuits rather than remove tissue. Candidates generally have chronic, severe, disabling OCD despite multiple adequate medication trials, augmentation and specialist exposure and response prevention. A meta-analysis published online in 2022 included 352 adults across 34 studies, including nine randomized trials: approximately 66% met response criteria at last follow-up, generally a Y-BOCS reduction of at least 35%. However, small controlled samples and substantial variation in targets, programming and follow-up constrain interpretation. Stimulation is adjustable and can be switched off, but implantation carries risks including haemorrhage and infection, while stimulation-related effects can include hypomania and impulsivity. (cdn.clinicaltrials.gov)
Ablative neurosurgery creates permanent, localized lesions. Anterior capsulotomy interrupts fibres in the anterior limb of the internal capsule; anterior cingulotomy targets the anterior cingulate cortex and cingulum. Lesions can be produced using radiofrequency techniques or stereotactic radiosurgery. A 2021 meta-analysis estimated response rates of 59% for capsulotomy and 36% for cingulotomy, but most included evidence was observational: these figures do not demonstrate superiority in a randomized comparison. Reported severe or permanent adverse effects included personality changes, cognitive deficits, brain oedema and cyst formation. Differences in lesion placement and adverse-event surveillance complicate comparisons between procedures. (pmc.ncbi.nlm.nih.gov)
Regulatory authorization does not imply equal evidential standards. On February 19, 2009, the FDA granted a humanitarian device exemption for Reclaim DBS as adjunctive treatment for adults with chronic, severe, treatment-resistant OCD who had failed at least three selective serotonin reuptake inhibitors. This pathway evaluates safety and probable benefit but exempts devices from the usual premarket effectiveness requirement. Clinical use requires institutional review board or appropriate local committee oversight. Surgical selection also entails careful assessment of treatment history, consent and capacity, particularly because ablation is irreversible and DBS requires continuing programming and hardware care. (accessdata.fda.gov)
Registered research includes individualized inferior frontal cortex targeting and symptom provocation in rTMS, exemplified by protocol NCT07198594. Durability remains an important question: Ilse Graat and colleagues’ 2021 DBS cohort followed 50 patients for a mean of 6.8 years, providing longer-term observational evidence but not a sustained sham-controlled comparison. Unresolved issues include optimal targets, maintenance schedules, predictors of response, and the frequency of delayed cognitive, behavioural and device-related complications. (cdn.clinicaltrials.gov)
Children and adolescents
Assessment requires attention to developmental level, not simply chronological age. Young children may describe a rule they “have to” follow without explaining the associated obsession, and difficulty discussing thoughts or estimating time can complicate severity ratings. Insight also varies: failure to recognise a fear as unreasonable must be interpreted in relation to cognitive maturity. In the Pediatric OCD Treatment Study for Young Children (POTS Jr), assessors used concrete, recent examples supplied by parents, sometimes asked about observable compulsions before obsessions, and combined child and caregiver accounts. The Children’s Yale–Brown Obsessive Compulsive Scale (CY-BOCS) provides a clinician-rated severity score from 0 to 40; developmentally adapted interviews allow its use even in some five-year-olds. Assessment also distinguishes OCD symptoms from other behaviours rather than attributing every repetitive act to the disorder. (pmc.ncbi.nlm.nih.gov)
Family involvement addresses both practical dependence on caregivers and family accommodation: relatives’ participation in rituals, repeated reassurance, or changes to household routines that help the child avoid feared situations. Such responses can relieve immediate distress while allowing avoidance and compulsions to continue. Family-based cognitive behavioural therapy therefore includes parent coaching, support for exposure homework, reinforcement of non-compulsive behaviour, and reduction of accommodation. Parents learn to tolerate the child’s temporary distress without completing rituals on the child’s behalf. For younger children, abstract explanations and numerical anxiety ratings can be replaced by drawings, a “worry monster” metaphor, or pictorial scales. These adaptations preserve the behavioural task—facing a feared situation without ritualising—while reducing its language and reasoning demands. (pmc.ncbi.nlm.nih.gov)
Direct trial evidence supports these adaptations. Jennifer Freeman and colleagues’ 2014 POTS Jr randomized controlled trial enrolled 127 children aged five to eight and compared 14 weeks of family-based CBT incorporating exposure and response prevention (ERP) with family-based relaxation treatment. At week 14, 72% of the CBT group and 41% of the relaxation group were rated “much improved” or “very much improved”; these were response rates, not rates of complete remission. Broader comparisons also favour ERP-containing treatments. Dale Steele and colleagues’ 2025 meta-analysis included 71 randomized trials: ERP reduced CY-BOCS scores by an estimated 10.5 points more than waitlist, while selective serotonin reuptake inhibitors (SSRIs) reduced scores by 4.4 points more than placebo. Combined ERP and an SSRI was probably more effective than an SSRI alone, with an estimated three-point advantage. Outcomes other than CY-BOCS severity were sparsely reported. (pubmed.ncbi.nlm.nih.gov)
Medication evidence does not establish that adding an SSRI improves every child’s outcome over adequate ERP alone. Matti Cervin and colleagues’ 2024 network meta-analysis, covering 30 trials and 2,057 young people, found no statistically significant difference between in-person CBT and combined CBT–serotonin reuptake inhibitor treatment; confidence in that comparison was low. NICE’s pediatric guidance places developmentally adapted, family-involved CBT at the centre of treatment and describes adding an SSRI after an inadequate response, with age-specific provisions for children aged eight to eleven and adolescents aged twelve to eighteen. Its prescribing framework includes low starting doses, gradual increases, and frequent monitoring, particularly for suicidal behaviour, self-harm, or hostility early in treatment. These safeguards are distinct from evidence about symptom reduction. (pubmed.ncbi.nlm.nih.gov)
Persistent symptoms require continuity rather than an automatic end to treatment at the pediatric service boundary. NICE’s transition framework specifies coordinated planning between children’s and adults’ services, developmentally appropriate participation by the young person, and involvement of caregivers where appropriate; transfer arrangements also encompass education, employment, and increasing independence. Continued improvement after an initial incomplete response is documented in the Nordic Long-term OCD Treatment Study. Karin Melin and colleagues followed 269 young people initially treated with CBT; nonresponders could receive additional CBT or sertraline. At three years, intent-to-treat analyses classified 90% as responders and 73% as being in clinical remission, defined respectively by CY-BOCS scores of 15 or below and 10 or below. These treated-cohort outcomes do not imply that childhood OCD invariably resolves, but demonstrate that failure to remit during an initial treatment course need not indicate persistent nonresponse. (nice.org.uk)
Course, prognosis and treatment-resistant OCD
Long-term outcome depends on whether improvement is measured as symptom reduction, remission at a particular assessment, or sustained recovery. A 2016 international consensus led by David Mataix-Cols defined remission as no longer meeting diagnostic criteria, with at most minimal, non-interfering symptoms, and recovery as maintaining this state for at least one year. In Jane Eisen and colleagues’ 2013 Brown Longitudinal Obsessive Compulsive Study of 213 treatment-seeking adults, 16.9% experienced full remission and 22.1% partial remission over five years; approximately 61% experienced neither. Remission required eight consecutive weeks of improvement, so these figures describe episodes of remission rather than permanent recovery. Subsequent relapse occurred in 45% of full remitters and 70% of partial remitters. A 2024 analysis of the Netherlands Obsessive-Compulsive Disorder Association cohort found full remission in approximately 30% at individual follow-ups, but only 14% across all three follow-up assessments over six years. (onlinelibrary.wiley.com)
Greater initial symptom severity and longer illness duration predicted a lower probability of remission in the Brown cohort. The Netherlands study also associated higher baseline severity and earlier onset with a chronic course. These are group-level associations, not reliable forecasts for an individual. Poor insight and psychiatric comorbidity have less consistent prognostic significance: neither independently predicted remission in the Brown study, whereas a 2025 study of concentrated exposure treatment in difficult-to-treat OCD associated poorer baseline insight with greater long-term symptom severity, but not strongly with immediate treatment outcome. Prognostic assessments therefore distinguish persistent illness from short-term treatment response and consider the population and treatment studied. (pmc.ncbi.nlm.nih.gov)
“Treatment-resistant” does not have a single universally applied threshold. The CANMAT–ICOCS international guideline describes commonly used definitions involving failure of one or two adequately dosed selective serotonin reuptake inhibitor (SSRI) trials lasting at least 8–12 weeks. More stringent definitions of “treatment-refractory” illness require failure of several serotonin reuptake inhibitors and augmentation strategies, including cognitive behavioural therapy with exposure and response prevention (ERP). Resistance to medication alone is therefore not equivalent to resistance to all established treatments. Before escalation, NICE guidance calls for checking medication adherence, prescribed dose, and interference from alcohol or substance use; its specialist assessment also reviews previous psychological treatment and coexisting conditions. (sciencedirect.com)
The NICE stepped-care pathway moves from an adequate initial SSRI or CBT–ERP course to combined treatment after insufficient improvement. It specifies review after an SSRI trial of approximately 12 weeks or CBT–ERP involving more than 10 therapist hours. Further non-response leads to another SSRI or clomipramine, followed by specialist multidisciplinary review after unsuccessful combined treatment and clomipramine. Specialist options include additional CBT–ERP and antipsychotic augmentation; the guideline does not prescribe a definitive sequence among these later options. Failure of one treatment modality need not imply failure of another: in a randomized study of adults remaining symptomatic on serotonin reuptake inhibitors, 50% assigned ERP augmentation reached minimal symptoms after acute treatment and six-month maintenance, compared with 5% assigned risperidone augmentation. (nice.org.uk)
Maintenance treatment addresses both residual symptoms and recurrence after improvement. NICE recommends continuing an effective SSRI for at least 12 months, then reviewing the need for continuation after 12 months following remission, taking account of illness severity, duration, previous episodes, residual symptoms, and psychosocial difficulties. Discontinuation is gradual rather than abrupt. In a 2022 randomized controlled trial led by Helen Blair Simpson, 101 adults who achieved wellness following ERP augmentation either tapered their medication or continued it. Average symptom outcomes at 24 weeks met the study’s non-inferiority criterion, but clinical worsening occurred in 45% of the taper group versus 24% of the continuation group. Similar mean outcomes therefore did not imply equivalent individual risks of deterioration. (nice.org.uk)
Psychological maintenance extends exposure practice and prevention of rituals beyond the acute treatment course. Self-directed practice is explicitly incorporated into treatment protocols: the Bergen four-day programme, for example, ends with planning self-exposures for the following three weeks. Maintenance sessions can revisit exposures, address remaining rituals, and provide relapse-prevention instruction. In the six-month augmentation study, participants with minimal symptoms received four weekly maintenance sessions followed by fortnightly sessions; those with residual symptoms could receive further intensive ERP before stepping down. Because that study did not separately randomize maintenance intensity, it supports the durability of the complete treatment programme rather than establishing how many booster sessions are necessary. (pmc.ncbi.nlm.nih.gov)
Burden, stigma and access to care
OCD-related disability extends beyond the time occupied by rituals: intrusive thoughts disrupt concentration, while avoidance restricts employment, education and social participation. Burden also falls on the family, whose members may provide repeated reassurance, participate in rituals or reorganize household routines around feared situations. This “family accommodation” is associated with greater symptom severity and impaired family functioning, although the relationship can operate in both directions. Economic losses therefore include both healthcare expenditure and reduced productivity. A study published in 1995 by Robert L. DuPont and colleagues estimated the annual United States cost of OCD at US$8.4 billion in 1990 dollars, including US$6.2 billion in indirect costs from lost productivity. These are historical estimates, not measurements of present-day expenditure. (pubmed.ncbi.nlm.nih.gov)
The treatment gap includes failure to recognize OCD, delayed help-seeking and receipt of nonspecific treatment after entering care. In Luana Marques and colleagues’ 2010 internet survey of 175 people with self-reported OCD, 60% reported receiving treatment for their symptoms, but most who obtained psychotherapy described “talk therapy” rather than the disorder’s established cognitive-behavioural treatment. Cost, lack of insurance, shame and doubts about effectiveness were prominent barriers. A 2025 German survey by Katharina Bey and colleagues, involving 276 adults, found a mean delay of 5.15 years before seeking psychotherapy and 5.58 years before recognition of OCD. Among 211 respondents who had received cognitive behavioural therapy, only 49.5% reported ever receiving therapist-guided exposure and response prevention (ERP). These self-selected surveys describe particular samples rather than national treatment rates. (onlinelibrary.wiley.com)
Structural barriers persist after symptoms are recognized. Specialist availability, waiting lists, treatment costs and difficulties locating appropriately trained clinicians can separate access to general mental health services from access to OCD-specific care. The German study identified long psychotherapy waiting times and insufficient provision of ERP as service-level obstacles. Inequalities also involve knowledge of referral pathways and anticipated discrimination: a 2012 study of 71 African American adults with OCD identified not knowing where to find help and concerns about discrimination as distinctive barriers relative to its European American comparison sample. Such findings distinguish practical access problems from reluctance to seek treatment. (bmcpsychiatry.biomedcentral.com)
Stigma can involve both trivialization and fear of disclosure. Public language such as “a little OCD” equates the disorder with neatness or ordinary preferences, obscuring distress and impairment; community accounts collected by the International OCD Foundation describe this framing as discouraging treatment-seeking. Unwanted sexual or aggressive obsessions create a different problem when their content is mistaken for desire or intent. Diagnostic misunderstanding is documented even among clinicians: Kimberly Glazier and colleagues’ 2015 vignette study of 208 primary-care physicians found an overall OCD misidentification rate of 50.5%, rising to 80.0% for an aggressive-obsession vignette. These experimental results measure recognition of written cases, not the frequency of misdiagnosis in routine practice. (iocdf.org)
Access initiatives address both clinician competence and delivery capacity. The International OCD Foundation’s Behavior Therapy Training Institute provides intensive ERP training, supplemented by expert-led online case-consultation groups and educational webinars. Digital services can reduce travel requirements and therapist time, but their effectiveness depends on the delivery model. In Lina Lundström and colleagues’ 2022 randomized controlled trial of 120 adults at two Stockholm specialist clinics, therapist-guided internet CBT was economically favourable compared with face-to-face CBT, although the trial did not conclusively establish noninferiority; unguided internet treatment produced poorer symptom outcomes. A separate Swedish economic evaluation published in 2021, involving 152 children and adolescents, found that internet CBT followed by in-person treatment for nonresponders reduced treatment costs by 39% without impairing effectiveness. This stepped-care model retains specialist treatment for those who need it rather than replacing it universally with self-help. (iocdf.org)
History of the concept
Nineteenth-century psychiatrists described obsessional states through competing categories rather than a single diagnosis. In his 1838 treatise, Jean-Étienne Dominique Esquirol discussed “Miss F.” under monomania: a circumscribed disturbance that could coexist with otherwise preserved reasoning. French descriptions subsequently emphasized pathological doubt and repetitive behaviour; Henri Legrand du Saulle’s La folie du doute avec délire du toucher (1875) brought together descriptions of persistent uncertainty and fears associated with touching. Carl Westphal’s influential German definition of 1877 characterized intrusive ideas as entering consciousness against the person’s will, despite otherwise intact intellectual functioning. These accounts helped distinguish obsessional experiences from beliefs accepted without resistance. In 1903, Pierre Janet’s Les obsessions et la psychasthénie placed obsessions within a broader syndrome of doubt, anxiety and impaired psychological functioning, which he explained through diminished “psychological tension,” a theoretical capacity for higher-level mental activity. (sciencedirect.com)
Sigmund Freud developed a different account within psychoanalysis, interpreting obsessional neurosis as an expression of unconscious conflict rather than primarily a disturbance of intellectual functioning. His 1909 Notes upon a Case of Obsessional Neurosis, commonly called the “Rat Man” case, described a patient troubled by fears that a punishment involving rats might be inflicted on his father or a woman he loved. Freud interpreted the symptoms through conflicting affection and hostility, sexual conflict, and defensive processes. In the wider psychoanalytic account, compulsive acts could represent attempts to undo unacceptable thoughts, while isolation and reaction formation separated ideas from their emotional significance or replaced an impulse with its opposite. These were historical explanatory theories, not evidence that unwanted obsessional thoughts reveal concealed intentions. The category “obsessional neurosis” nevertheless became an enduring part of twentieth-century psychiatric terminology. (lutecium.org)
The behavioural turn shifted attention from the presumed symbolic meaning of symptoms to the circumstances maintaining rituals. Victor Meyer’s 1966 report, Modification of Expectations in Cases with Obsessional Rituals, described two patients treated by confronting feared situations while preventing their customary rituals. This approach became exposure and response prevention (ERP); a controlled study by Stanley Rachman and colleagues in 1971 involved ten inpatients with chronic symptoms. The underlying account held that rituals persist because their immediate reduction of distress reinforces repetition. Cognitive approaches subsequently examined why intrusive thoughts acquire threatening significance. Paul Salkovskis’s 1985 cognitive-behavioural analysis proposed that intrusive thoughts act as stimuli for appraisals involving responsibility or blame for harm. This helped integrate behavioural procedures with interventions addressing interpretations of thoughts within cognitive behavioural therapy. (sciencedirect.com)
Diagnostic classification changed alongside these explanatory models. DSM-III, published in 1980, classified obsessive–compulsive disorder among anxiety disorders, replacing the earlier organizing framework of neuroses with more explicitly defined diagnostic categories. OCD remained in the anxiety-disorders chapter through DSM-IV. DSM-5, published in 2013, introduced a separate chapter, “Obsessive-Compulsive and Related Disorders.” The American Psychiatric Association explained this change as reflecting evidence of relationships among disorders involving obsessive preoccupation or repetitive behaviour, alongside distinctions from other anxiety disorders. The chapter brought OCD together with body dysmorphic disorder and hair-pulling disorder, and included newly established diagnoses of hoarding disorder and excoriation disorder; these remained separate conditions rather than variants of OCD. (pmc.ncbi.nlm.nih.gov)
Popular culture also became a site of debate about the concept. In As Good as It Gets (1997), Jack Nicholson’s character Melvin Udall performs contamination-avoidance and other rituals that disrupt everyday activities and relationships. A 2012 analysis by Noah C. Berman at Massachusetts General Hospital’s Center for OCD and Related Disorders credited the film with depicting distress and functional interference, while observing that the character’s exaggerated eccentricities could blur the distinction between symptoms and personality. The television detective Adrian Monk likewise became the subject of research: a 2012 study examined fans’ responses through parasocial relationships and beliefs about the programme’s influence on others. Such discussion concerned not merely whether fictional rituals resembled clinical symptoms, but how character construction and audience identification shaped the public meaning of the disorder. (en.wikipedia.org)
Open questions and current research
A central unresolved question is how genetic susceptibility, altered brain connectivity and learned compulsive behaviour combine to produce different clinical presentations and treatment responses. Association studies can identify candidate mechanisms without establishing whether an observed difference causes symptoms, follows from them or reflects medication exposure. A 2025 genome-wide association study led by Nora Strom combined 53,660 OCD cases and 2,044,417 controls, identifying 30 independent genome-wide significant loci and 249 potential effector genes. These findings provide targets for investigating biological pathways rather than a diagnostic genetic test or a treatment-selection rule. All 28 contributing cohorts were of European ancestry, and case identification ranged from clinical assessment to self-reported diagnosis, limiting generalisation across populations and clinical settings. (doi.org)
The search for biomarkers must distinguish group-level abnormalities from measurements that reliably inform decisions about an individual. In a 2023 ENIGMA-OCD study, resting-state functional connectivity data from 1,024 patients and 1,028 healthy controls across 28 samples yielded classification areas under the receiver-operating-characteristic curve of 0.567–0.673, where 0.5 represents chance discrimination. Classification was better for medicated than unmedicated patients, illustrating the difficulty of separating illness-related signals from treatment-related differences. The findings also challenge the assumption that statistically significant differences in magnetic resonance imaging necessarily constitute useful diagnostic markers. Combining imaging modalities and identifying more homogeneous clinical subgroups remain proposed approaches, rather than established clinical tools. (nature.com)
Research on personalised treatment asks a more specific question than whether a patient is likely to improve: which intervention offers that patient the greater benefit? A randomised controlled trial published in the January 2023 issue of the American Journal of Psychiatry examined pretreatment resting-state connectivity in 116 adolescents and adults assigned to 12 sessions of exposure and response prevention (ERP) or stress-management therapy. Lower connectivity between the ventromedial prefrontal cortex and subcortical regions was associated with greater improvement during ERP, whereas higher connectivity favoured improvement during the comparator treatment. This treatment-dependent association illustrates a possible route to selection biomarkers, but it does not establish a validated scan-based prescribing algorithm. Approximately 52% of participants were taking serotonergic medication, and adolescents and adults were sampled within restricted age ranges, complicating extrapolation to other patients. (pmc.ncbi.nlm.nih.gov)
International guidelines agree on the principal first-line treatments but organise their use differently. The United Kingdom’s NICE guideline CG31, published in 2005, explicitly stratifies initial treatment by functional impairment: low-intensity cognitive behavioural therapy incorporating ERP for mild impairment, a choice between more intensive CBT and a selective serotonin reuptake inhibitor for moderate impairment, and combined treatment for severe impairment. The WFSBP guideline, published online in 2022 and in a 2023 journal issue, identifies SSRIs and CBT as first-line treatments, clomipramine among second-line medications, and several augmentation options for resistant cases. Its international panel evaluated 291 OCD randomised trials. Agreement on effective interventions therefore does not eliminate uncertainty about their optimal sequence or the circumstances in which combination treatment is necessary. (nice.org.uk)
Direct comparisons help clarify what apparent first-line nonresponse means. In Helen Blair Simpson and colleagues’ 2013 trial, 100 adults with persistent symptoms despite serotonin reuptake inhibitor treatment received eight weeks of additional ERP, risperidone or placebo. ERP produced substantially greater symptom reduction than either pill condition, showing that failure to obtain sufficient benefit from medication does not establish resistance to psychological treatment. However, this two-centre, short-term trial does not determine the best sequence for every resistant presentation or explain the biological basis of nonresponse. (pmc.ncbi.nlm.nih.gov)
Study design remains a major constraint: small imaging samples, medication confounding, variation between scanning sites, short treatment periods and inconsistent outcome definitions impede comparison and replication. David Mataix-Cols and colleagues’ 2016 international consensus sought to standardise response as at least a 35% reduction on the Yale–Brown Obsessive Compulsive Scale together with a Clinical Global Impression–Improvement rating of 1 or 2. Subsequent individual-patient-data research has examined whether these thresholds optimally correspond to clinical improvement. Distinguishing symptom response from remission, and measuring durability rather than only immediate post-treatment change, remain important methodological questions. (nature.com)
References
- Psychiatry.org - What is the DSM?psychiatry.org
- Table 3.13, DSM-IV to DSM-5 Obsessive-Compulsive Disorder Comparisonncbi.nlm.nih.gov
- Obsessive-Compulsive Disorder: When Unwanted Thoughts or Repetitive Behaviors Take Over - National Institute of Mental Healthnimh.nih.gov
- Psychiatry.org - What Is are Obsessive-Compulsive and Related Disorders?psychiatry.org
- DSM Historypsychiatry.org
- Obsessive Compulsive and Related Disorderspsychiatry.org
- Obsessive-Compulsive and Related Disorderspsychiatry.org
- Selected Health Conditions and Likelihood of Improvement with Treatmentncbi.nlm.nih.gov
- Diagnostic and Statistical Manual of Mental Disorders and OCDocduk.org
- Diagnostic and Statistical Manual of Mental Disorders, Fifth Editionhelp-curriculum.com
- Specialty knowledge and competency standards for pharmacotherapy for adult obsessive-compulsive disorderpmc.ncbi.nlm.nih.gov
- DSM-5 Guidebookw1.med.cmu.ac.th
- Obsessive-Compulsive Disorder: When Unwanted Thoughts or Irresistible Actions Take Overinfocenter.nimh.nih.gov
- Towards a definitive symptom structure of obsessive-compulsive disorder: A factor and network analysis of 87 distinct symptoms in 1366 individualsportal.research.lu.se
- Towards a definitive symptom structure of obsessive−compulsive disorder: a factor and network analysis of 87 distinct symptoms in 1366 individualspmc.ncbi.nlm.nih.gov
- Recommendations: Obsessive-compulsive disorder and body dysmorphic disorder: treatmentnice.org.uk
- Obsessive-Compulsive Disorder: When Unwanted Thoughts or Irresistible Actions Take Overnimh.nih.gov
- Practice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorderpsychiatry.org
- Rates and correlates of nonadherence to treatment in obsessive-compulsive disorderresearch.monash.edu
- Changes in insight throughout the natural four-year course of obsessive-compulsive disorder and its association with OCD severity and quality of lifepmc.ncbi.nlm.nih.gov
- The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication.pubmed.ncbi.nlm.nih.gov
- Obsessive-compulsive disorder in the World Mental Health surveysbmcmedicine.biomedcentral.com
- Age of onset in obsessive-compulsive disorder: admixture analysis with a large sample.pubmed.ncbi.nlm.nih.gov
- Obsessive-Compulsive Disorder (OCD)msdmanuals.com
- A Clinical Staging Model for Obsessive–Compulsive Disorder: Is It Ready for Prime Time?pmc.ncbi.nlm.nih.gov
- Longitudinal Course of Obsessive-Compulsive Symptoms During the Covid-19 Pandemic: A Systematic Review of Three Years of Prospective Cohort Studiespmc.ncbi.nlm.nih.gov
- Duration of Untreated Illness in Patients with Obsessive–Compulsive Disorder and Its Impact on Long-Term Outcome: A Systematic Reviewpmc.ncbi.nlm.nih.gov
- The cross national epidemiology of obsessive compulsive disorder. The Cross National Collaborative Grouppubmed.ncbi.nlm.nih.gov
- Pattern of obsessive-compulsive disorder in eastern Saudi Arabiapubmed.ncbi.nlm.nih.gov
- The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replicationcpb-us-w2.wpmucdn.com
- Psychiatry.org - What are Eating Disorders?psychiatry.org
- Clinical Descriptions and Diagnostic Requirements for ICD-11 Mental, Behavioural or Neurodevelopmental Disordersdrugsandalcohol.ie
- Repetitive behaviors in Tourette's syndrome and OCD with and without tics: what are the differences?pubmed.ncbi.nlm.nih.gov
- A case-controlled study of repetitive thoughts and behavior in adults with autistic disorder and obsessive-compulsive disorder.pubmed.ncbi.nlm.nih.gov
- Does clozapine cause or worsen obsessive compulsive symptoms? An analysis and literature reviewpmc.ncbi.nlm.nih.gov
- Population-based, multigenerational family clustering study of obsessive-compulsive disorderpubmed.ncbi.nlm.nih.gov
- Are punitive parenting and stressful life events environmental risk factors for obsessive-compulsive symptoms in youth? A longitudinal twin studypmc.ncbi.nlm.nih.gov
- Genome-wide analyses identify 30 loci associated with obsessive–compulsive disorderpmc.ncbi.nlm.nih.gov
- Genome-wide analyses identify 30 loci associated with obsessive–compulsive disorderdoi.org
- Risk factors prospectively associated with adult obsessive-compulsive symptom dimensions and obsessive-compulsive disorderpubmed.ncbi.nlm.nih.gov
- Risk Factors Prospectively Associated with Adult Obsessive-Compulsive Symptom Dimensions and Obsessive-Compulsive Disorderpmc.ncbi.nlm.nih.gov
- Cortical glutamate and GABA are related to compulsive behaviour in individuals with obsessive compulsive disorder and healthy controlsnature.com
- Provocation of obsessive–compulsive symptoms: a quantitative voxel-based meta-analysis of functional neuroimaging studiespmc.ncbi.nlm.nih.gov
- Emotional processing in obsessive-compulsive disorder: A systematic review and meta-analysis of 25 functional neuroimaging studiespmc.ncbi.nlm.nih.gov
- Serotonin transporters in obsessive-compulsive disorder: a positron emission tomography study with [(11)C]McN 5652pubmed.ncbi.nlm.nih.gov
- Reduced availability of serotonin transporters in obsessive-compulsive disorder correlates with symptom severity - a [11C]DASB PET studypubmed.ncbi.nlm.nih.gov
- Error-processing and inhibitory control in obsessive-compulsive disorder: a meta-analysis using statistical parametric mapspmc.ncbi.nlm.nih.gov
- Error Processing and Inhibitory Control in Obsessive-Compulsive Disorder: A Meta-analysis Using Statistical Parametric Mapsescholarship.org
- A cognitive theory of obsessionspubmed.ncbi.nlm.nih.gov
- Mechanisms of exposure and response prevention in obsessive-compulsive disorder: effects of habituation and expectancy violation on short-term outcome in cognitive behavioral therapypmc.ncbi.nlm.nih.gov
- Repeated checking causes memory distrustpubmed.ncbi.nlm.nih.gov
- Cognitive Mediation of Symptom Change in Exposure and Response Prevention for Obsessive-Compulsive Disorderpubmed.ncbi.nlm.nih.gov
- Evidence-Based Assessment of Obsessive–Compulsive Disorderpmc.ncbi.nlm.nih.gov
- The Yale-Brown Obsessive Compulsive Scale. I. Development, Use, and Reliabilitybrainphysics.com
- The Yale-Brown Obsessive-Compulsive Scale: Factor Structure of a Large Samplepmc.ncbi.nlm.nih.gov
- Cognitive Mediation of Symptom Change in Exposure and Response Prevention for Obsessive Compulsive Disorderpmc.ncbi.nlm.nih.gov
- The Yale-Brown Obsessive Compulsive Scale. II. Validitypubmed.ncbi.nlm.nih.gov
- The Obsessive-Compulsive Inventory: development and validation of a short versionpubmed.ncbi.nlm.nih.gov
- Assessment of obsessive-compulsive symptom dimensions: development and evaluation of the Dimensional Obsessive-Compulsive Scalepubmed.ncbi.nlm.nih.gov
- Assessing Sexually Intrusive Thoughts: Parsing Unacceptable Thoughts on the Dimensional Obsessive-Compulsive Scalepmc.ncbi.nlm.nih.gov
- The Brown Assessment of Beliefs Scale: reliability and validitypubmed.ncbi.nlm.nih.gov
- Family accommodation of obsessive-compulsive symptoms: instrument development and assessment of family behaviorpubmed.ncbi.nlm.nih.gov
- Operational Definitions of Treatment Response and Remission in Obsessive-Compulsive Disorder Capture Meaningful Improvements in Everyday Lifepmc.ncbi.nlm.nih.gov
- International OCD Foundation | Exposure and Response Prevention (ERP)iocdf.org
- International OCD Foundation | Exposure and Response Prevention (ERP)iocdf.org
- International OCD Foundation | The Inhibitory Learning Approach to Exposure and Response Preventioniocdf.org
- Behavioral avoidance predicts treatment outcome with exposure and response prevention for obsessive-compulsive disorderpubmed.ncbi.nlm.nih.gov
- Concentrated ERP for Patients With Difficult‐to‐Treat OCD: Insight as a Predictor of Acute and Long‐Term Outcomespmc.ncbi.nlm.nih.gov
- Randomized comparative study of group versus individual cognitive behavioural therapy for obsessive compulsive disorderpubmed.ncbi.nlm.nih.gov
- A Randomized Controlled Trial of Concentrated ERP, Self-Help and Waiting List for Obsessive-Compulsive Disorder: The Bergen 4-Day Treatmentpubmed.ncbi.nlm.nih.gov
- Effect of Internet-Based vs Face-to-Face Cognitive Behavioral Therapy for Adults With Obsessive-Compulsive Disorder: A Randomized Clinical Trialpubmed.ncbi.nlm.nih.gov
- A pilot randomized controlled trial of videoconference-assisted treatment for obsessive-compulsive disorderpubmed.ncbi.nlm.nih.gov
- DailyMed - SERTRALINE tablet, film coateddailymed.nlm.nih.gov
- DailyMed - SERTRALINE tablet, film coateddailymed.nlm.nih.gov
- A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorderpubmed.ncbi.nlm.nih.gov
- High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trialpubmed.ncbi.nlm.nih.gov
- DailyMed - CLOMIPRAMINE HYDROCHLORIDE capsuledailymed.nlm.nih.gov
- DailyMed - CLOMIPRAMINE HYDROCHLORIDE capsuledailymed.nlm.nih.gov
- Antipsychotic Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: An Update Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trialspubmed.ncbi.nlm.nih.gov
- Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled studypubmed.ncbi.nlm.nih.gov
- Memantine augmentation of sertraline in the treatment of symptoms and executive function among patients with obsessive-compulsive disorder: A double-blind placebo-controlled, randomized clinical trialpubmed.ncbi.nlm.nih.gov
- Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorderpubmed.ncbi.nlm.nih.gov
- Cognitive-Behavioral Therapy vs Risperidone for Augmenting Serotonin Reuptake Inhibitors in Obsessive-Compulsive Disorder: A Randomized Clinical Trialpmc.ncbi.nlm.nih.gov
- FDA permits marketing of transcranial magnetic stimulation for treatment of obsessive compulsive disorderfda.gov
- Treating refractory obsessive compulsive disorder with cathodal transcranial direct current stimulation over the supplementary motor area: a large multisite randomized sham-controlled double-blind studypubmed.ncbi.nlm.nih.gov
- Effectiveness and safety of neuroablation for severe and treatment-resistant obsessive–compulsive disorder: a systematic review and meta-analysispmc.ncbi.nlm.nih.gov
- Approval order: Reclaim Deep Brain Stimulation for Obsessive Compulsive Disorder Therapyaccessdata.fda.gov
- HDE Approvalsfda.gov
- Humanitarian Device Exemption (HDE) Postmarket Activitiesfda.gov
- Research Proposal: NCT07198594cdn.clinicaltrials.gov
- Long-term Outcome of Deep Brain Stimulation of the Ventral Part of the Anterior Limb of the Internal Capsule in a Cohort of 50 Patients With Treatment-Refractory Obsessive-Compulsive Disorderpubmed.ncbi.nlm.nih.gov
- Cognitive outcomes following functional neurosurgery in refractory OCD patients: a systematic reviewpmc.ncbi.nlm.nih.gov
- The Pediatric Obsessive Compulsive Disorder Treatment Study for Young Children (POTS jr): Developmental Considerations in the Rationale, Design, and Methodspmc.ncbi.nlm.nih.gov
- Family-Based Treatment of Early Childhood OCD: The Pediatric OCD Treatment Study Junior (POTS Jr.) Randomized Controlled Trialpmc.ncbi.nlm.nih.gov
- Children’s and Parents’ Ability to Tolerate Child Distress: Impact on Cognitive Behavioral Therapy for Pediatric Obsessive Compulsive Disorderpmc.ncbi.nlm.nih.gov
- Family-based treatment of early childhood obsessive-compulsive disorder: the Pediatric Obsessive-Compulsive Disorder Treatment Study for Young Children (POTS Jr)—a randomized clinical trialpubmed.ncbi.nlm.nih.gov
- Efficacy and acceptability of cognitive-behavioral therapy and serotonin reuptake inhibitors for pediatric obsessive-compulsive disorder: a network meta-analysispubmed.ncbi.nlm.nih.gov
- Quality statement 2: Coordinated transition plannice.org.uk
- Recommendations: Transition from children’s to adults’ services for young people using health or social care servicesnice.org.uk
- Treatment Gains Are Sustainable in Pediatric Obsessive-Compulsive Disorder: Three-Year Follow-Up From the NordLOTSpubmed.ncbi.nlm.nih.gov
- Five-Year Course of Obsessive-Compulsive Disorder: Predictors of Remission and Relapsepmc.ncbi.nlm.nih.gov
- Six-Month Outcomes from a Randomized Trial Augmenting Serotonin Reuptake Inhibitors with Exposure and Response Prevention or Risperidone in Adults with Obsessive-Compulsive Disorderpmc.ncbi.nlm.nih.gov
- Maintenance of Wellness in Patients With Obsessive-Compulsive Disorder Who Discontinue Medication After Exposure/Response Prevention Augmentation: A Randomized Clinical Trialpmc.ncbi.nlm.nih.gov
- The Bergen 4-Day Treatment (B4DT) for Obsessive-Compulsive Disorder: Outcomes for Patients Treated After Initial Waiting List or Self-Help Interventionpmc.ncbi.nlm.nih.gov
- A Multi-Site Study of Family Functioning Impairment in Pediatric Obsessive-Compulsive Disorderpmc.ncbi.nlm.nih.gov
- Prevalence and predictors of family accommodation in obsessive–compulsive disorder in an Indian settingpmc.ncbi.nlm.nih.gov
- Economic costs of obsessive-compulsive disorderpubmed.ncbi.nlm.nih.gov
- Help-seeking behavior, treatment barriers and facilitators, attitudes and access to first-line treatment in German adults with obsessive-compulsive disorderpubmed.ncbi.nlm.nih.gov
- Help-seeking behavior, treatment barriers and facilitators, attitudes and access to first-line treatment in German adults with obsessive-compulsive disorderlink.springer.com
- Addressing ‘I'm so OCD’ in the COVID eraiocdf.org
- Obsessive-Compulsive Disorder Misdiagnosis among Mental Healthcare Providers in Latin Americapmc.ncbi.nlm.nih.gov
- Half of obsessive-compulsive disorder cases misdiagnosed: vignette-based survey of primary care physicianspubmed.ncbi.nlm.nih.gov
- International OCD Foundation: IOCDF Training Instituteiocdf.org
- On the history of obsessive compulsive disorders: their place in the nosological classifications up to the beginning of the 20th centurypubmed.ncbi.nlm.nih.gov
- The history of OCDocduk.org
- Notes upon a Case of Obsessional Neurosis (1909)lutecium.org
- Cognitive behavioral therapy of obsessive-compulsive disorderpmc.ncbi.nlm.nih.gov
- A history of anxiety: from Hippocrates to DSMpmc.ncbi.nlm.nih.gov
- Psychiatry.org — Frequently Asked Questionspsychiatry.org
- Obsessive Compulsive and Related Disorderspsychiatry.org
- Obsessive–compulsive disorderen.wikipedia.org
- Is This “As Good as It Gets?”: Popular Media’s Representation of OCDmghocd.org
- The functional connectome in obsessive-compulsive disorder: resting-state mega-analysis and machine learning classification for the ENIGMA-OCD consortiumnature.com
- Resting-State Connectivity and Response to Psychotherapy Treatment in Adolescents and Adults with OCD: A Randomized Clinical Trialpmc.ncbi.nlm.nih.gov
- World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders – Version 3. Part II: OCD and PTSDpubmed.ncbi.nlm.nih.gov
- Towards an international expert consensus for defining treatment response, remission, recovery and relapse in obsessive-compulsive disorderpubmed.ncbi.nlm.nih.gov
- An evaluation of treatment response and remission definitions in adult obsessive-compulsive disorder: A systematic review and individual-patient data meta-analysispure.amsterdamumc.nl